Common Contracts
4 similar First Supplemental Indenture contracts by Cytokinetics Inc, Inseego Corp., Retrophin, Inc., Xeris Biopharma Holdings, Inc.
XERIS PHARMACEUTICALS, INC. and as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of June 30, 2020First Supplemental Indenture • October 5th, 2021 • Xeris Biopharma Holdings, Inc. • Pharmaceutical preparations • New York
This Supplemental Indenture (as defined below) is being executed and delivered pursuant to Sections 2.01 and 2.02 of the Base Indenture (as defined below) to establish the terms, and provide for the issuance, of a new series of Securities (as defined in the Base Indenture) constituting the Company’s 5.00% Convertible Senior Notes due 2025 (the “Notes”).
INSEEGO CORP. and WILMINGTON TRUST, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of May 12, 2020 3.25% Convertible Senior Notes due 2025First Supplemental Indenture • May 12th, 2020 • Inseego Corp. • Communications equipment, nec • New York
THIS FIRST SUPPLEMENTAL INDENTURE, dated as of May 12, 2020 (the “Supplemental Indenture”), to the Indenture, dated as of May 12, 2020 (the “Base Indenture” and, as amended, modified and supplemented by this Supplemental Indenture, the “Indenture”), between Inseego Corp., a Delaware corporation, as issuer (the “Company”) and Wilmington Trust, National Association, a national banking association, as trustee (the “Trustee”).
CYTOKINETICS, INCORPORATED and U.S. BANK NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of November 13, 2019 4.00% Convertible Senior Notes due 2026First Supplemental Indenture • November 13th, 2019 • Cytokinetics Inc • Pharmaceutical preparations • New York
THIS SUPPLEMENTAL INDENTURE, dated as of November 13, 2019 (the “Supplemental Indenture”), to the Indenture, dated as of November 13, 2019 (the “Base Indenture” and, as amended, modified and supplemented by this Supplemental Indenture, the “Indenture”), between Cytokinetics, Incorporated, a Delaware corporation, as issuer (the “Company”) and U.S. Bank National Association, as trustee (the “Trustee”).
RETROPHIN, INC. and U.S. BANK NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of September 10, 2018 2.50% Convertible Senior Notes due 2025First Supplemental Indenture • September 10th, 2018 • Retrophin, Inc. • Pharmaceutical preparations • New York
THIS SUPPLEMENTAL INDENTURE, dated as of September 10, 2018 (the “Supplemental Indenture”), to the Indenture, dated as of September 10, 2018 (the “Base Indenture” and, as amended, modified and supplemented by this Supplemental Indenture, the “Indenture”), between Retrophin, Inc., a Delaware corporation, as issuer (the “Company”) and U.S. Bank National Association, as trustee (the “Trustee”).
